Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK-positive (ALK+) solid tumors in a histology-agnostic setting.

TPS3155Background: Anaplastic lymphoma kinase (ALK) fusions are found in 3–8% of non-small cell lung cancers (NSCLC) and 0.2% of other tumor types. Alectinib is a selective, CNS-active ALK tyrosin...